A Phase 3 interventional study of Vortioxetine and Placebo in Major Depressive Disorder, sponsored by Takeda. Completed at 33 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-13.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 14th largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 3rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2008, is one of 16 in phase 3, and was the 1st registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took vortioxetine.
The study enrolled 600 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):
All participants were asked to take one capsule at the same time each day throughout the study.
This multi-center trial was conducted in the United States. The overall time to participate in this study was approximately 94 days. Participants made 8 visits to the clinic, and were contacted by telephone 1 week, 2 weeks, and 4 weeks after the last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has 1 or more the following:
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.
Drug: Placebo
Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.
Drug: Vortioxetine
Encapsulated immediate-release tablets.
Also known as: Lu AA21004, Brintellix®
Vortioxetine placebo-matching capsules.
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment and center as fixed factors and the baseline value as a covariate.
Time frame: Baseline and Week 6
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 3, 4 and 5
Percentage of Responders in HAM-D24 Total Score by Study Visit
A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Percentage of Participants in MADRS Remission at Week 6
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
Time frame: Week 6
Percentage of Participants With a Sustained Response in HAM-D24
A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 5 and at least 50% decrease from Baseline at Week 6.
Time frame: Baseline to Week 6
Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least square means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Change From Baseline in Hamilton Anxiety Scale (HAM-A)
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least squares means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 4 and 6.
Change From Baseline in Clinical Global Impression Scale-Severity of Illness
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Clinical Global Impression Scale-Global Improvement Scale
The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)
The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4 and 6.
Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Week 6
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Week 6
Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
Time frame: Baseline and Week 6
Participants took part in the study at 47 investigative sites in the United States from 07 April 2008 to 12 November 2008.
| Milestone | Placebo | Vortioxetine |
|---|---|---|
| Started | 300 | 300 |
| Safety set | 298 | 299 |
| Full analysis set | 286 | 292 |
| Completed | 236 | 244 |
| Not completed | 64 | 56 |
| Withdrew: Adverse event | 11 | 9 |
| Withdrew: Lack of efficacy | 6 | 11 |
| Withdrew: Non-compliance with study drug | 2 | 3 |
| Withdrew: Protocol deviations | 11 | 5 |
| Withdrew: Voluntary withdrawal | 12 | 8 |
| Withdrew: Lost to follow-up | 22 | 17 |
| Withdrew: Reason not specified | 0 | 3 |
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment and center as fixed factors and the baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6 | -13.87 ± 0.662 | -14.61 ± 0.650 |
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Week 1 (n=281, 286) | -6.03 ± 0.394 | -5.96 ± 0.387 |
| Week 2 (n= 286, 291) | -9.30 ± 0.505 | -9.05 ± 0.496 |
| Week 3 (n= 286, 292) | -11.05 ± 0.545 | -11.73 ± 0.536 |
| Week 4 (n= 286, 292) | -12.33 ± 0.579 | -12.66 ± 0.568 |
| Week 5 (n=286, 292) | -13.11 ± 0.628 | -13.98 ± 0.617 |
A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.
| percentage of participants | Placebo | Vortioxetine |
|---|---|---|
| Week 1 (n=281, 286) | 7.8 | 7.0 |
| Week 2 (n=286, 291) | 23.8 | 21.0 |
| Week 3 (n=286, 292) | 31.8 | 32.9 |
| Week 4 (n=286, 292) | 39.2 | 37.0 |
| Week 5 (n=286, 292) | 44.4 | 43.8 |
| Week 6 (n=286, 292) | 46.2 | 46.2 |
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
| percentage of participants | Placebo | Vortioxetine |
|---|---|---|
| Percentage of Participants in MADRS Remission at Week 6 | 32.2 | 29.1 |
A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 5 and at least 50% decrease from Baseline at Week 6.
| percentage of participants | Placebo | Vortioxetine |
|---|---|---|
| Percentage of Participants With a Sustained Response in HAM-D24 | 21.0 | 19.5 |
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least square means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Week 1 (n=281, 286) | -6.88 ± 0.418 | -6.38 ± 0.412 |
| Week 2 (n=286, 291) | -10.57 ± 0.530 | -9.82 ± 0.523 |
| Week 3 (n=286, 292) | -12.48 ± 0.583 | -12.76 ± 0.575 |
| Week 4 (n=286, 292) | -13.72 ± 0.624 | -13.70 ± 0.615 |
| Week 5 (n=286, 292) | -14.40 ± 0.673 | -15.12 ± 0.664 |
| Week 6 (n=286, 292) | -15.48 ± 0.708 | -15.80 ± 0.698 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least squares means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Week 1 (n=281, 286) | -3.25 ± 0.288 | -3.21 ± 0.284 |
| Week 2 (n=286, 291) | -4.92 ± 0.343 | -4.77 ± 0.338 |
| Week 4 (n=286, 292) | -6.52 ± 0.393 | -6.88 ± 0.387 |
| Week 6 (n=286, 292) | -7.60 ± 0.419 | -7.84 ± 0.413 |
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Week 1 (n=281, 286) | -0.47 ± 0.045 | -0.40 ± 0.044 |
| Week 2 (n=286, 291) | -0.82 ± 0.061 | -0.82 ± 0.060 |
| Week 3 (n=286, 292) | -1.07 ± 0.069 | -1.08 ± 0.067 |
| Week 4 (n=286, 292) | -1.25 ± 0.073 | -1.20 ± 0.072 |
| Week 5 (n=286, 292) | -1.28 ± 0.079 | -1.36 ± 0.077 |
| Week 6 (n=286, 292) | -1.46 ± 0.085 | -1.46 ± 0.083 |
The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Week 1 (n=281, 286) | 3.38 ± 0.048 | 3.46 ± 0.047 |
| Week 2 (n=286, 291) | 3.09 ± 0.062 | 3.08 ± 0.061 |
| Week 3 (n=286, 292) | 2.90 ± 0.066 | 2.84 ± 0.065 |
| Week 4 (n=286, 292) | 2.74 ± 0.070 | 2.75 ± 0.069 |
| Week 5 (n=286, 292) | 2.74 ± 0.073 | 2.65 ± 0.071 |
| Week 6 (n=286, 292) | 2.61 ± 0.076 | 2.57 ± 0.075 |
The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Week 1 (n=279, 286) | -2.81 ± 0.214 | -2.73 ± 0.210 |
| Week 4 (n=284, 292) | -4.18 ± 0.272 | -4.05 ± 0.267 |
| Week 6 (n=284, 292) | -4.56 ± 0.313 | -4.97 ± 0.307 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Physical functioning | 5.47 ± 1.277 | 6.87 ± 1.264 |
| Role - physical | 11.73 ± 1.569 | 14.41 ± 1.549 |
| Bodily pain | 10.77 ± 1.460 | 10.39 ± 1.445 |
| General health | 7.65 ± 0.985 | 7.37 ± 0.975 |
| Vitality | 18.00 ± 1.455 | 17.34 ± 1.440 |
| Social functioning | 21.34 ± 1.687 | 22.01 ± 1.667 |
| Role - emotional | 19.43 ± 1.756 | 20.76 ± 1.732 |
| Mental health | 18.98 ± 1.401 | 20.00 ± 1.385 |
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine |
|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6 | -6.61 ± 0.548 | -6.69 ± 0.557 |
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
| participants | Placebo | Vortioxetine |
|---|---|---|
| Baseline: Any resource use | 82 | 77 |
| Baseline: Any hospitalization-related services | 1 | 0 |
| Baseline: Hospitalization related to depression | 1 | 0 |
| Baseline: Any sick leave | 16 | 21 |
| Baseline: Sick leave related to depression | 9 | 13 |
| Week 6: Any resource use | 58 | 41 |
| Week 6: Any hospitalization-related service | 3 | 1 |
| Week 6: Hospitalization related to depression | 0 | 0 |
| Week 6: Any sick leave | 7 | 7 |
| Week 6: Sick leave related to depression | 3 | 2 |
Collected over Treatment-emergent adverse events are defined as adverse events whose onset occurred or intensity increased after the first dose of double-blind study drug through 30 days after permanent discontinuation of double-blind study drug.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/298 (1.3%) | 142/298 (47.7%) |
| Vortioxetine | — | 7/299 (2.3%) | 168/299 (56.2%) |
| Event | Placebo | Vortioxetine |
|---|---|---|
| Puncture site infectionInfections and infestations | 1/298 | 0/299 |
| Laryngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/298 | 0/299 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/298 | 0/299 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/298 | 0/299 |
| Drug hypersensitivityImmune system disorders | 0/298 | 1/299 |
| Herpes zosterInfections and infestations | 0/298 | 1/299 |
| InjuryInjury, poisoning and procedural complications | 0/298 | 1/299 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/298 | 1/299 |
| Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/298 | 1/299 |
| Cerebrovascular accidentNervous system disorders | 0/298 | 1/299 |
| Event | Placebo | Vortioxetine |
|---|---|---|
| NauseaGastrointestinal disorders | 28/298 | 57/299 |
| HeadacheNervous system disorders | 45/298 | 51/299 |
| DiarrhoeaGastrointestinal disorders | 21/298 | 34/299 |
| Dry mouthGastrointestinal disorders | 19/298 | 25/299 |
| DizzinessNervous system disorders | 22/298 | 19/299 |
| Abdominal painGastrointestinal disorders | 3/298 | 12/299 |
| SomnolenceNervous system disorders | 10/298 | 11/299 |
| DyspepsiaGastrointestinal disorders | 10/298 | 5/299 |
| InsomniaPsychiatric disorders | 9/298 | 6/299 |
| ConstipationGastrointestinal disorders | 6/298 | 9/299 |
| Age Continuous(years) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| Mean | 42.4 ± 12.70 | 42.5 ± 13.04 | 42.4 ± 12.86 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| Female | 164 | 186 | 350 |
| Male | 136 | 114 | 250 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| Caucasian (White, including Hispanic) | 216 | 209 | 425 |
| Black | 78 | 81 | 159 |
| Asian | 4 | 8 | 12 |
| American Indian or Alaska Native | 2 | 1 | 3 |
| Native Hawaiian/ Other Pacific Islander | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| Hispanic/Latino | 36 | 34 | 70 |
| Non-Hispanic/Non-Latino | 264 | 266 | 530 |
| Region of Enrollment(participants) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| United States | 300 | 300 | 600 |
| Weight(kg) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| Mean | 89.53 ± 23.326 | 86.63 ± 23.528 | 88.08 ± 23.453 |
| Height(cm) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| Mean | 170.36 ± 9.815 | 168.67 ± 9.815 | 169.51 ± 9.843 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Vortioxetine | Total |
|---|---|---|---|
| Mean | 30.84 ± 7.675 | 30.48 ± 8.217 | 30.66 ± 7.946 |
7 further baseline measures are reported on the registry.
The record gives a start of Apr 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine